Business Wire

GOCARDLESS

4.5.2022 01:03:13 CEST | Business Wire | Press release

Share
GoCardless Welcomes Paul Stoddart as President

GoCardless , a leader in direct bank payment solutions, today announced the appointment of Paul Stoddart as President. Stoddart joins from Mastercard where he was President of its New Payment Platforms, Executive Chairman of Vocalink and a Member of the Mastercard Management Committee. In his new role at GoCardless he will have global responsibility for the go-to-market organisation including the Strategy, Sales, Product, Marketing and Customer teams, with a view to accelerating growth and achieving the company’s ambition to become the world’s bank payment network.

Stoddart brings a wealth of experience to GoCardless. He was named as Chief Executive Officer of Vocalink after its acquisition by Mastercard and subsequently promoted to President of Mastercard’s New Payment Platforms where he led the establishment and growth of a business unit that expanded Mastercard’s role in payments beyond cards to account-to-account payments. Prior to Vocalink he was Co-Head of Corporate Finance at Barclaycard. He also spent 10 years at NatWest where he held a number of senior roles including in their merchant acquiring and e-commerce business, Worldpay.

His appointment comes as the company broadens its offering of direct bank payment solutions for both one-off and recurring payments and builds out its suite of payment intelligence products to help businesses manage their payments more effectively. GoCardless will benefit from Stoddart’s expertise as it doubles down on account-to-account payments, with plans to release its Variable Recurring Payment feature shortly in the UK and expand Instant Bank Pay, its solution for one-off payments, across Europe.

Hiroki Takeuchi, co-founder and CEO at GoCardless, said : “This year marks an inflection point at GoCardless as we expand beyond recurring payments to serve a broader range of customer segments and payment use cases. Having the right people to lead us on this journey is critical as we scale our business, develop new products and services with open banking, and explore new markets. Paul has a unique depth of experience across both card and non-card payments and is well-positioned to help us seize the opportunities that will make GoCardless a force to be reckoned with in the payments space.”

Paul Stoddart, President at GoCardless, said: “GoCardless is in an incredibly exciting place right now. Hiroki and the team have already built a successful business by solving real customer problems. They have the foundations of a global bank pay network that will go from strength to strength as more businesses and people embrace account-to-account payments from bank debit to open banking-enabled payments. We will continue to push the boundaries of what’s possible in payments. In this new role at GoCardless I’ll have the opportunity to be part of the team building the new generation of payment solutions to do just that, with customer needs at the forefront.”

Stoddart’s appointment comes as GoCardless continues to accelerate its growth following its latest funding round of US$312 million in February. In the intervening months, GoCardless released its second open banking-enabled feature, Verified Mandates, in the UK and Success+, its ‘payment intelligence’ product which uses machine learning to identify the optimal day to recover failed payments, in the US.

In the UK, GoCardless recently signed its first Variable Recurring Payment customers and plans to introduce VRPs in both ‘sweeping’ and ‘non-sweeping’ forms over the coming months. By mid-2022, GoCardless will also integrate PayTo into its global bank payment platform in time for the regulated launch in Australia.

About GoCardless

GoCardless is a global leader in direct bank payment solutions, making it easy to collect both recurring and one-off payments directly from customers' bank accounts through direct debit and open banking. The GoCardless global payments network and technology platform take the pain out of getting paid for 70,000 businesses worldwide, from multinational corporations to small businesses. Each year GoCardless processes over US$30 billion of payments across more than 30 countries. GoCardless is headquartered in the UK, with additional offices in Australia, France, Germany and the United States. For more information, please visit www.gocardless.com and follow us on Twitter @GoCardless .

© 2022 GoCardless Ltd. All Rights Reserved. GoCardless is a registered trademark of GoCardless Ltd. in multiple countries. Third party trademarks mentioned above are owned by their respective companies. Unless explicitly identified as such, nothing in this press release should be construed to the contrary, or as an approval, endorsement or sponsorship by any third parties of GoCardless Ltd. or any aspect of this press release.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye